Previously, no randomized controlled trials investigated the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) as the primary endpoint in patients with diabetes and chronic kidney disease. In the FLOW trial, Perkovic et al. showed that once-weekly semaglutide reduced kidney failure, kidney-related death, and cardiovascular death by 24% as compared with placebo in patients with type 2 diabetes at high risk of renal progression. 1 .
Keyphrases
- chronic kidney disease
- end stage renal disease
- type diabetes
- phase iii
- randomized controlled trial
- study protocol
- rheumatoid arthritis
- clinical trial
- peritoneal dialysis
- cardiovascular disease
- glycemic control
- phase ii
- atomic force microscopy
- insulin resistance
- double blind
- disease activity
- metabolic syndrome
- interstitial lung disease
- systemic lupus erythematosus
- systemic sclerosis
- single molecule